Esperto Medical Secures Significant Series A Investment
Esperto Medical™, Inc., a pioneering healthtech startup focusing on critical care and remote patient monitoring, has announced the successful closing of an oversubscribed Series A investment round. This round was co-led by industry leaders Catalyst Health Ventures and Bold Capital Partners, with notable participation from Wavemaker Three-sixty Health, Free Flow Ventures, Fund@Caltech, and Maverick Ventures.
Funding to Propel Innovative Monitoring Technology
The funds garnered through this investment will significantly advance the productization and clinical testing of Esperto's innovative Resonance Sonomanometry™ (RSM) technology. This groundbreaking approach leverages sound waves at various frequencies to assess blood pressure within arteries, making it a calibration-free solution that offers ease of use and high accuracy.
What Is Resonance Sonomanometry?
The RSM technology is designed to provide continuous blood pressure monitoring without the variability common in traditional methods. Its noninvasive nature enhances its appeal for various patient demographics, as it can be applied comfortably on different parts of the body, including arms, legs, and neck. This flexibility opens new avenues for cardiovascular monitoring, allowing healthcare providers to cater to a wider patient base efficiently.
Expert Insights on RSM's Potential
Dr. Alaina Rajagopal, cofounder and Chief Medical Officer at Esperto, emphasized the device's versatility, stating, "RSM's adaptability fosters its use across various patient types. It is poised to transform cardiovascular monitoring for a diverse group of patients. This technology marks a significant step forward in critical care."
Strong Leadership for Future Development
Joshua Phillips, cofounder and Managing Partner at Catalyst Health Ventures, noted the unique advantages RSM holds in the healthcare market. He expressed excitement over its prospective applications, stating, "RSM represents a new frontier in monitoring technology with compelling competitive benefits, not only for hospital use but also for personal care applications." Moreover, Phillips and Dr. Helen McBride, Partner at Bold Capital Partners, will join the board of directors, bringing their extensive expertise in healthcare investment and technology to support Esperto's mission.
Looking Toward Commercialization
Dr. McBride shared her enthusiasm for the team's commitment to advancing RSM technology, having witnessed its development firsthand during its early stages at Caltech. "Esperto has assembled a fantastic team to further RSM's journey towards clinic implementation and beyond. I am excited to assist in their progress toward a transformative approach to patient monitoring," she stated.
Aditya Rajagopal, PhD, cofounder and CEO of Esperto Medical, expressed gratitude towards the new investors. He stated, "We are delighted to welcome Catalyst Health Ventures, Bold Capital Partners, and other investors to Esperto. Our goal is to enhance RSM's capabilities for patients, healthcare providers, and systems, tackling a persistent clinical challenge: accurate, noninvasive, and continuous blood pressure monitoring."
About Esperto Medical™
Recognized as Octane's Best Emerging Disruptor of 2024, Esperto is dedicated to redefining healthcare and expanding accessibility through cutting-edge noninvasive diagnostic technologies. The healthcare industry is ripe for innovation, yet current practices for vital sign monitoring remain limited. Esperto aims to liberate healthcare professionals and patients from outdated methods, paving the way for modern solutions to vital monitoring tasks.
Frequently Asked Questions
What does Esperto Medical specialize in?
Esperto Medical specializes in developing innovative monitoring solutions for critical care and remote patient monitoring.
What is Resonance Sonomanometry™ technology?
RSM is a patented technology that utilizes sound waves to measure blood pressure noninvasively and without the need for calibration.
Who are the investors in the Series A financing?
The Series A financing was co-led by Catalyst Health Ventures and Bold Capital Partners, along with support from various other investors.
What types of patients can benefit from RSM technology?
RSM technology is designed to be adaptable for use on a diverse range of patients, optimizing blood pressure monitoring across different demographics.
What are Esperto Medical's future plans?
Esperto aims to advance RSM technology toward commercialization to bring efficient and accurate blood pressure monitoring solutions to healthcare providers and patients.
